Archiv: Sanofi (corporation)


17.11.2021 - 18:12 [ Heise.de ]

Biotechnologie, Staat und Kapital

Dieser Markt ließe sich unermesslich steigern, sollte die Propaganda, dass die gesamte Menschheit (B. Gates) und in Deutschland fast die gesamte Bevölkerung (A. Merkel) geimpft werden solle und auch müsse, umgesetzt werden. Deshalb schätzt das Finanz- und Analyseunternehmen „Morningstar“ für 2021 zu erwartenden Umsatz von 67 Milliarden US-Dollar für Covid-19-Impfstoffe. Der Umsatz der Rüstungsindustrie umfasste 2019 166 Mrd. US-Dollar.

Zwei dieser Biotech-Unternehmen sollen näher betrachtet werden: Biontech und Curevac.

29.10.2020 - 05:51 [ marketscreener.com ]

EU warns not enough COVID vaccines for all in Europe until 2022

(27.10.2020)

The EU has so far secured doses of the potential vaccines being developed by AstraZeneca, Sanofi and Johnson & Johnson. It has also said it is in talks with …

02.09.2020 - 13:12 [ Times of India ]

In change of tack, EU leaves door open to COVID vaccines purchase through WHO

The move could allow EU governments to secure vaccines from companies that are not negotiating with Brussels, such as U.S. firms Merck, Inovio and Novavax. They are all in talks with the WHO scheme, dubbed COVAX, but have so far not been reported to be involved in negotiations with the EU Commission.

11.07.2020 - 18:33 [ theGrayzone.com ]

Why the Bill Gates global health empire promises more empire and less public health

Behind a veil of corporate media PR, the Gates Foundation has served as a vehicle for Western capital while exploiting the Global South as a human laboratory. The coronavirus pandemic is likely to intensify this disturbing agenda.

15.03.2020 - 22:51 [ Genetic Engineering and Biotechnology News - genengnews.com ]

CureVac, Sanofi Pasteur, and In-Cell-Art Collaborate on €33.1M DARPA-Supported Vaccine Program

(November 15, 2011)

The four-year DARPA-supported program will exploit CureVac’s RNActive technology along with In-Cell-Art’s nanoparticle expertise and Sanofi’s vaccine development capabilities.

The option agreement signed between Sanofi and CureVac in parallel with the DARPA collaboration covers pre-agreed license terms for the development of vaccines against a number of predefined pathogens.